1 The effects and binding characteristics of a series of chimeric galanin-neuropeptide Y (NPY) peptides were examined in various preparations known to contain a predominant population of either Y1 or Y2 receptors for NPY or galanin receptors. 2 NPY suppressed the electrically stimulated twitches of the rat vas deferens (Y2 receptors), while galanin enhanced the electrically stimulated twitches. The galanin-NPY peptides M 32 (galanin(1-13)-NPY(25-36)), M69A (galanin(1-13)-Lys-[sNH-Gly-NPY(4-l)]NPY(25-36)) and M88 (galanin(1-12)-Ala-NPY(25-36)) evoked a concentration-dependent suppression of the electrically stimulated twitches. These chimeric peptides were about equipotent with NPY, while NPY (13-36) was about five times less potent than NPY itself. Also a stochiometric combination of the N-and C-terminal fragments NPY (1-24)NH2 and NPY (25-36) (each at 1 iM) was inactive in vas deferens. M120 (galanin (1-13)-NPY(14-36) (1 gLM) did not affect the NPY-mediated suppression of the stimulated twitches. 3 NPY evoked a concentration-dependent contraction in the guinea-pig isolated caval vein (Y1 receptors), while galanin (. 1 jIM) was inactive. M32, M69A and M88 induced a slight contraction at very high concentrations only (. 0.3 M), while M120 was inactive at 1 pM. None of the four chimeric peptides affected the contraction evoked by NPY. 4 Since the number of NPY receptors in the rat vas deferens and guinea-pig caval vein were too low, the affinities of the galanin-NPY peptides for [3H]-NPY binding sites were examined in membranes from rat brain areas known to contain predominant populations of Y1 receptors (cerebral cortex) and Y2 receptors (hippocampus), respectively. The chimeric peptides M32, M69A, M88, M120 and NPY (13-36) all had higher affinities for hippocampal binding sites than for cerebral cortical binding sites. These peptides were 90-440 times less potent than NPY at cerebral cortical binding sites and 15-125 times less potent than NPY at hippocampal binding sites. The most selective chimeric peptide was M32, which had a 20 fold higher affinity for hippocampal than for cerebral cortical binding sites.
Introduction
Neuropeptide Y (NPY) occurs in many central and peripheral neurones, including a prominent population of sympathetic neurones (e.g. Sundler et al., 1986; De Quidt et al., 1986 ) from which NPY is released in conjunction with noradrenaline. At the sympathetic neuroeffector junction NPY activates receptors referred to as Y1 and Y2 (for a review see Grundemar & Hikanson, 1993) . The postjunctional receptor, which is mainly of the Y. type, causes vasoconstriction (cf. Grundemar et al., 1992; 1993b) . The Y1 receptor is quite stringent in its demand on the N-terminal end of the NPYmolecule; the loss of Tyr' in (NPY 2-36) results in a marked loss of potency and shorter fragments are several orders of magnitude less potent than NPY itself (Grundemar et al., 1992) . Recently, the rat and human Y1 receptor has been cloned and shown to belong to the family of G-protein coupled receptors (Eva et al., 1990; Herzog et al., 1992; Larhammar et al., 1992) . Pharmacological studies using cell I Author for correspondence.
cultures expressing cloned Y1 receptors have confirmed the necessity for an intact N-terminal portion of NPY (Krause et al., 1992; Larhammar et al., 1992) . The prejunctional NPY receptor, which is of the Y2 type, is known to suppress the release of transmitters from sympathetic nerve endings (e.g. Wahlestedt et al., 1986; Grundemar & HAkanson, 1990) . In contrast to the Y1 receptor, the Y2 receptor recognizes a wide range of C-terminal NPY fragments (Grundemar & HAkanson, 1990) . A common feature of both Y1 and Y2 receptors is the requirement for an amidated NPY C-terminus (Tyri6-NH2) (cf. Grundemar et al., 1993b) .
Several attempts have been made to synthesize Y1 and Y2 receptor-selective ligands. [Pro3INPY and variants thereof have been shown to interact with the Y1 but not with the Y2 receptor Krstenansky et al., 1990; Grundemar et al., 1993a,b) . Fairly selective Y2 receptor agonists have been developed based on NPY analogues having the centre part of the molecule substituted by a spacer sequence (Beck et al., 1989; Krstenansky et al., 1989; 1990; Beck-Sickinger et al., 1992; Grundemar et al., 1993a) . How-ever, none of these analogues seem to be more selective or potent than NPY (13-36), which is virtually inactive at Y, receptors and about 10 times less potent than NPY (1-36) at Y2 receptors (e.g. Grundemar et al., 1993b) . Some chimeric peptides have recently been shown to behave as potent antagonists at galanin receptors Langel et al., 1992) and at vasoactive intestinal polypeptide (VIP) receptors (Gozes et al., 1991) , respectively. In these cases the recognition units of the peptides (such as galanin (1-12) or VIP (7-28) were joined to another peptide to yield high affinity peptide antagonists for galanin receptors and for VIP receptors, respectively. We have synthesized a series of galanin-NPY chimeric peptides, based on the information that at least the Y2 type NPY receptors recognize a range of C-terminal NPY fragments (Abens et al., 1989; Grundemar & Hakanson, 1990) and that galanin receptors require for recognition the N-terminal (1-12) fragment of galanin .
The chimeric peptide, M32 (galanin (1-13)-NPY (25-36)) is a high affinity galanin receptor ligand and results from a recent 'H n.m.r. study (Arvidsson et al., 1993) have suggested that this peptide may assume a hair pin loop similar to that of NPY (cf. . The structural similarity of the galanin-NPY analogue M32 to NPY suggested that it may act as a ligand at NPY receptors. We have examined possible interactions of M32 and related chimeric galanin-NPY peptides in various experimental set ups known to contain either of the two NPY receptor types, Y1 and Y2. In addition, we describe some preliminary results regarding the ability of these peptides to interact with galanin receptors.
Methods

Functional experiments
Male Sprague-Dawley rats (200-250 g) were killed and the prostatic segment of each vas deferens was cut out and placed in Krebs solution of the following composition (mM): NaCl 133, NaHCO3 16.3, KCl 4.7, MgC2 1.0, NaH2PO4 1.4, CaCl2 2.5 and glucose 7.8. Segments (1.5 cm in length) were mounted vertically on Perspex holders in a 7 ml tissue bath maintained at 33°C. The solution was bubbled continuously with 95% 02 and 5% CO2, yielding a pH of 7.4. The mechanical activity was recorded isometrically with a Grass FT03 force displacement transducer and a Grass model 7 polygraph. The preparations were allowed to equilibrate for about 60 min with a tension of about 10 mN. Electrical field (submaximal) stimulation with square wave pulses (25 V, 1 ms and 0.15 Hz) was then applied by means of a pair of platinum electrodes connected to a Grass S4C stimulator. As soon as a series of pulses gave identical responses, increasing doses of a peptide were added in a cumulative manner. The preparation was stimulated repeatedly until the effect of each concentration of peptide attained a stable level. The inhibition of the electrically evoked twitches for each peptide concentration was expressed as a percentage of the response of a parallel control preparation not exposed to peptides. A new concentration of each peptide was added every 5 min.
Caval vein Guinea-pigs (Dunklin-Hartley, 350-540 g) were killed and the proximal part of the inferior caval vein close to the right auricle was removed. The vessel was divided into three circular segments (each 2 mm wide) which were transferred to a constant temperature bath (37°C), containing Krebs solution of the following composition (in mM): NaCl 119, KC1 4.6, CaCl2 1.5, MgCl2 1.2, NaHCO3 15.0, NaH2PO0 1.2 and D-glucose 6.0. The solution was bubbled continuously with 95% 02 and 5% CO2, yielding a pH of 7.4. The vascular segments were mounted on two L-shaped stainless steel wires (0.1 mm diameter), one of which was connected to a force-displacement transducer (Grass Instrument FT 03C) for continuous tension recording on a Grass polygraph (Hogestatt et al., 1983) . The resting tension was gradually adjusted to 2 mN. The contractile capacity of the blood vessel was examined by adding an isotonic 124 mM K+ Krebs solution (NaCl replaced by KCl); the resulting contraction which was maximal served as an internal control. After washing out the K+-enriched solution, increasing doses of the different peptides were added in a cumulative manner. Each vascular segment was exposed to one peptide only. Contractile responses were expressed in relation to the initial K+-evoked contraction. The IC50 values for each peptide (concentration eliciting 50% of the maximum response) were estimated by linear interpolation of the concentrationresponse curve in the 10-90% range.
Since bacitracin (1 mg ml-') did not affect the responses to the peptides, the peptidase inhibitor was not present in subsequent smooth muscle experiments.
Binding experiments
Male Sprague-Dawley rats (180-200 g) were decapitated and the hippocampus, cerebral cortex and hypothalamus were rapidly dissected and frozen at -70'C. The tissue was homogenized on ice with a tight fitting teflon-glass homogenizer in 0.32 M sucrose buffered with 5 mM HEPES (pH 7.4). The homogenate was diluted and centrifuged at 1000 g for 10 min. The 
Peptide synthesis
The linear chimeric peptides were assembled in a stepwise manner in a solid support (MBHA resin to achieve the C-terminally amidated peptides) using t Boc chemistry on an Applied Biosystems Model 431A Peptide Synthesizer on a 0.1 mmol (small) scale. The synthesis, cleavage from resin and purification of the peptides have been described in detail before Langel et al., 1992 We confirmed that NPY suppressed, while galanin enhanced electrically stimulated twitches (Lundberg & Tatemoto, 1982; Ohhashi & Jacobowitz, 1985) . The galanin-NPY peptides M32 (galanin(1-13)-NPY(25-36)),M69A (galanin (1-13)-Lys-(eNH-Gly-NPY(4-l)]NPY(25-36)) and M88 (galanin(1-12)-Ala-NPY(25-36)) evoked a concentration-dependent suppression of the electrically-stimulated twitches. For the primary structure of the chimeric peptides, see Table 1 . The three chimeric peptides were about equipotent with NPY ( Figure 1 and Table 2 ). In comparison, NPY (13-36) was about five times less potent than NPY itself (Figure 1 and Table 2 ). Also a stochiometric combination of the N-and C-terminal fragments NPY (1-24)NH2 and NPY (25-36) (each at 1 gM) was inactive (n = 4) (data not shown). M120 (galanin (1-13)-NPY(14-36)) (1 JtM) did not affect the NPY-evoked suppression of the stimulated twitches (n = 4) (data not shown).
Effects on the guinea-pig caval vein As shown in Figure 2 , NPY (< 0.1 M) evoked a concentration-dependent contraction in the caval vein, while galanin (< 1 SM) was inactive. M32, M69A and M88 induced slight contractions at concentrations > 0.3 gM, while M120, was inactive at 1MM (Figure 2) Figure 3 shows that while NPY bound with equally high affinity to cortical 
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M120
Galanin(l-13)-NPY(14-36) (Table 3 ). The 'tertraheder shaped' or branched galanin-NPY chimeric ligand M69A, which carries both NPY (1-4) and NPY (25-36) along with the galanin (1-12) sequence, bound to both cerebral cortical and hippocampal binding sites with a similar affinity in the low nanomolar range (Table 3) . When the C-terminal portion of the chimeric peptide comprises NPY (13-36), i.e. peptide M120, the affinities for cerebral cortical and hippocampal NPY-binding sites, respectively, were found to be similar (Table 3) .
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Affinity for galanin binding sites andfunctional effects
As shown in Table 3 the chimeric peptides M32, M88 and M69A were at least equipotent with galanin at ['251 ]-galanin binding sites in the rat hypothalamus, while M120 was about 10 times less potent than galanin. In a series of preliminary experiments M32, M69A and M88 (>0.1 JIM) and galanin contracted the rat isolated jejunum (data not shown).
Discussion
The electrically stimulated rat vas deferens has been a much used model for the study of Y2 receptors (e.g. Wahlestedt et al., 1986; Danho et al., 1988; Grundemar & HAkanson, 1990; Jorgensen et al., 1990; Grundemar et al., 1993a) . In the present series of experiments we confirmed that vas deferens, contains both Y2 and galanin receptors, which inhibit and facilitate electrically-evoked contractions in the rat vas deferens, respectively (Ohhashi & Jacobowitz, 1985; Grundemar & Hikanson, 1990) . The Y2 receptor is not stringent in its requirement for the N-terminal part of NPY, since NPY (13-36) is a fairly potent agonist. However, NPY (25-36) and shorter fragments are virtually inactive (e.g. Grundemar & HAkanson, 1990) . In the present study we examined whether the presence of N-terminal fragments of NPY may facilitate Y2 receptor activation: NPY (1-24)NH2 and NPY (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) were administered in stochiometric amounts simultaneously. However, there was no response to the mixture of the two NPY fragments, suggesting that the N-and C-terminal parts must be covalently linked in order to activate Y2 receptors in the rat vas deferens.
Galanin receptors appear to recognize the N-terminal part of the galanin molecule (Ekblad et al., 1985; Fox et al., 1988; Murakami et al., 1989; Xu et al., 1989; Kuwahara et al., 1990) . The rat vas deferens, thus, contains both inhibitory Y2 receptors and enhancing galanin receptors. Using various chimeric galanin-NPY peptides with N-terminal galanin fragments (1-12) linked to C-terminal fragments of NPY, it was found that M32 (galanin(1-13)-NPY(25-36)), M69A (galanin (1-13)-Lys-[eNH-Gly-NPY(4-1)]NPY(25-36)) and M88 (galanin(l-12)-Ala-NPY(25-36)) potently and effectively suppressed the stimulated twitches in the rat vas deferens. In fact, the three chimeric galanin-NPY peptides were equipotent with NPY itself. However, these results contrast with the low ligand binding affinity of the chimeric peptides at NPY binding sites in the hippocampus, which is known to contain a predominant population of Y2 receptors (Sheikh et al., 1989; Dumont et al., 1990; Aicher et al., 1991 (Grundemar et al., 1992; 1993a) . In agreement with findings obtained with other blood vessels, this study has shown that galanin was inactive in the caval vein (Ekblad et al., 1985) . M32, M69A and M88 evoked a slight contraction at very high concentrations only (0.3;Mm), while M120 was inactive at . 1 MM. Neither chimeric peptide affected the response to NPY. Thus, the chimeric peptides do not appear to be Y. receptor antagonists. The binding of the galanin-NPY peptides in the rat cerebral cortex, which is known to contain Y. receptors (Dumont et al., 1990; Aicher et al., 1991) confirmed that the chimeric galanin-NPY peptides have very low affinities (90-440 fold lower than NPY) for Y1 type binding sites. The results from the NPY binding and bioactivity studies both support the suggestion that, in order to activate the Y1 receptor, the ligand must present the proximity of N-and C-terminal ends of NPY to the signal epiptope Grundemar et al., 1993a,b) .
The present study shows that the chimeric galanin-NPY peptides all had a very high affinity for galanin receptors in the hypothalamus. Several studies have suggested that various N-terminal galanin containing chimeric peptides act as antagonists at certain galanin receptors Langel et al., 1992) . Using a series of N-and C-terminal galanin fragments, it has recently been proposed that they recognize different galanin receptor subtypes in rat pancreas and jejunum, respectively . In this study we have confirmed results from a very recent report that N-terminal galanin chimeric peptides, instead of being galanin antagonists, act as galanin agonists in the rat jejunum (Gu et al., 1993) .
In conclusion, the N-terminal portion (1-12) of galanin seems to permit a steric conformation of the attached NPY (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) 
